Rubicon inaugurates India's first cGMP facility for CTS

Mumbai, Aug 19 (UNI) Rubicon Research Private Limited today inaugurated its cGMP Clinical Trial Supplies (CTS) facility at Ambernath in Thane district, near here.

With this, Rubicon vertically integrated its business model in the area of formulation development.

''With CTS, Rubicon is taking an important step towards completing the spectrum of pharmaceutical development offerings. We envision a strong structure, where we are the perfect strategic partners for our clients, where we create novel scientific applications as well as product life cycle management option for our clients and partners,'' Rubicon Research Private Limited CEO Pratibha Pilgaonkar said during her welcome speech at the inaugural ceremony.

Dr Clive Wilson, Prof of Pharmaceutics in the Department of Pharmaceutical Sciences at University of Strathclyde, Glasgow, Scotland, during his key note address stressed upon the importance on the value and nature of Clinical Trials and significance of cGMP.

He emphasized that ''with the many variables that may become apparent in the conduct of a clinical trial, the goal of cGMP and several other product related factors is to maintain the study integrity from a drug product perspective.'' This is a first of its kind facility in India, offering the entire gamut of Clinical supplies, from Clinical manufacturing to Clinical Trial Material (CTM) depot.

From the new facility, Rubicon would also extend its expertise and services in its current core areas of Formulation Development, Analytical Development, Stability Studies and Technology Transfer for its clients.

UNI AR GS ZA VKG1943